Kanebo Cosmetics To Be Absorbed By Parent Kao In Wake Of Recalls
This article was originally published in PharmAsia News
Executive Summary
Kanebo Cosmetics, which ran into trouble with Japan's government over one of its drug-related cosmetic lines, is being largely absorbed by Kao, its parent company, to be turned into a marketing company.
You may also be interested in...
What’s Next After 20 Years Of NICE?
Meindert Boysen, head of NICE’s Centre For Health Technology Evaluation, shares advice for companies aiming to get their medicine to patients. His golden rules: engage in early advice and be more realistic about pricing.
Vildagliptin Prices Fall By Over 70% In India Post Patent Expiry
Vildagliptin formulation prices fall by over 70% following the expiry of a patent held by Novartis in India. The innovator, meanwhile, is cashing in on co-marketing agreements with Indian partners like USV and Cipla
Medtechs Enter The Decade Of Digital, Consumers and Wellness
For providers and medtech manufacturers alike, the decade ahead will be a time of coming to terms with digital technologies and integrating new methods of payment. Quality of service delivery remains the market entry criterion, but companies will have to adapt to evolving health care delivery models. The stakes are implausibly high. Will they be able to capitalize on the changes in a market that is more competitive and unpredictable than ever?
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: